Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Total Voting Rights

6 Jan 2021 10:27

RNS Number : 7656K
Oncimmune Holdings PLC
06 January 2021
Β 

6 January 2021

Β 

Β 

Oncimmune Holdings plc

Β 

("Oncimmune" or the "Company")

Β 

Total Voting Rights

Β 

Β 

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.

Β 

As at 31 December 2020, the Company's issued share capital was 63,662,446 ordinary shares of Β£0.01 each with voting rights. The Company does not hold any shares in treasury.

Β 

The above figure of 63,662,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Β 

Β 

Β 

For further information:

Β 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

Β 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

Β 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

Β 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Β 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TVREAEFKEAKFEFA
Date   Source Headline
13th Feb 20187:00 amRNSInterim Results for the half year ended 30 Nov 17
5th Feb 20187:01 amRNSUniversity of Nottingham share sale
5th Feb 20187:00 amRNSHoldings in Company
2nd Feb 20184:45 pmRNSTotal Voting Rights
29th Jan 20187:00 amRNSFirst tranche of £10m equity investment
23rd Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
22nd Jan 201811:21 amRNSResult of General Meeting
9th Jan 20187:00 amRNSAppointment of Non-Executive Director
4th Jan 20187:30 amRNSNotice of General Meeting
2nd Jan 20187:00 amRNSFramework agreement, licence and £10m investment
21st Dec 20177:00 amRNSValidation of EarlyCDT®-Liver test
30th Nov 20173:53 pmRNSHolding(s) in Company
29th Nov 20179:55 amRNSResult of AGM
27th Nov 20177:00 amRNSAppointment of joint brokers
24th Nov 20177:00 amRNSSatisfaction of Delayed Completion Placing
22nd Nov 20177:00 amRNSDeadline extended for Delayed Completion Placing
16th Nov 20177:00 amRNSDistribution agreement signed for Iran
9th Nov 20177:00 amRNSLaunch of "Finger Stick" Sample Collection
3rd Nov 20177:00 amRNSAnnual Report and Accounts and AGM Notification
27th Oct 201710:32 amRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSResults for the year ended 31 May 2017
18th Oct 20177:00 amRNSDistribution Agreement in Poland
10th Oct 201711:15 amRNSHoldings in Company
10th Oct 20177:00 amRNSNotice of Results
27th Sep 20172:11 pmRNSSuccessful £5.0m placing
26th Sep 20175:12 pmRNSProposed placing to raise up to £5.3m
19th Sep 20177:00 amRNSEarlyCDT®-Lung Kit Distribution Agreements
18th Sep 20177:00 amRNSData presented at the 11th Annual ILCA
14th Sep 20177:00 amRNSBusiness Update
29th Aug 20177:00 amRNSOncimmune and Scancell Present Data
20th Jul 20171:59 pmRNSExercise of Options & 2007 Share Option Scheme
7th Jul 20177:00 amRNSHolding(s) in Company
5th Jun 20177:00 amRNSBusiness Update and New Distribution Agreements
31st May 20177:00 amRNSCE Mark for EarlyCDT-Lung Kit
17th May 20177:00 amRNSGRANT OF OPTIONS
28th Apr 20177:00 amRNSFirst Distribution Agreements Signed
24th Apr 20179:18 amRNSGRANT OF OPTIONS
3rd Apr 20177:00 amRNSAppointment of Senior VP, MA & Reimbursement
3rd Apr 20177:00 amRNSGRANT OF OPTIONS AND DEALING BY PDMR
29th Mar 20173:35 pmRNSHolding(s) in Company
10th Feb 20177:00 amRNSInterim Results
8th Feb 20177:00 amRNSNotice of Interim Results
6th Dec 20167:00 amRNSPositive interim data from NHS Screening Trial
30th Nov 20165:47 pmRNSPUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
30th Nov 201610:47 amRNSResult of Annual General Meeting
8th Nov 20166:25 pmRNSGrant of options
7th Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSNotice of Full Year Results
11th Oct 20167:00 amRNSBoard Appointment
22nd Sep 20167:00 amRNSAppointment of Chief Commercial Officer Asia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.